PDCD1 and colitis: The risk of recurrence was higher (a) in those who experienced a longer duration of symptoms in the initial episode of ICI colitis; (b) in those whose primary episode of ICI colitis was while receiving anti-PD-1/L1 therapy and (c) in those who required second-line immunosuppressive therapy for their primary episode of ICI colitis (including the need for infliximab or vedolizumab).